Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran
Frontiers in Pharmacology · 15.11.2024 · 15
DOI: 10.3389/fphar.2024.1454612 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 15.11.2024. Verfasst von Zhuan Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
The impact of genetic polymorphisms in the ABCB1 and CES1 genes on dabigatran plasma concentrations remains a subject of debate, and the purpose of this study was to quantitatively assess the effects of genetic polymorphisms on dabigatran esters in healthy Chinese subjects employed a population pharmacokinetic (PopPK) approach.
Methods
In total, 1,926 pharmacokinetic (PK) samples from 123 healthy individuals who were given 150 mg of dabigatran orally during a fasting state or postprandially were analyzed using the PopPK model. A two-compartment model with first-order absorption was found to adequately describe the PK data.
Results
The results showed that covariates food intake and ABCB1 SNP rs4148738 were shown to have statistically significant impacts. Specifically, in postprandial administration increased lag time (ALAG) and clearance (CL) by 2.65% and 0.51%, respectively, and decreased absorption rate constant (KA) by 0.24%. Additionally, in subjects with CT genotype ABCB1 (rs4148738), the central ventricular volume of distribution (V 2 ) was increased by 0.38%.
Conclusion
In summary, the PopPK model developed in this study was robust and effectively characterized the pharmacokinetics of dabigatran in healthy Chinese adults, demonstrating that both food and ABCB1 genetic variation significantly influence the absorption and plasma concentration levels of dabigatran.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
- School of Pharmacy, Guizhou Medical University, Guiyang, China.
- Department of Pharmacology and System Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Zitieren
APA
Yang, Z., Tan, W. R., Li, Q., Wang, Y., Liu, S., Chen, L., Zhou, Y., Zeng, C., Zeng, Y., Xiong, Y., Zhang, Q., Li, N., Du, P., Liu, L., Chen, J., & He, Y. (2024). Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1454612
Vancouver
Yang Z, Tan WR, Li Q, Wang Y, Liu S, Chen L, et al. Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1454612
BibTeX
@article{Yang2024,
author = {Yang, Zhuan and Tan, Wen Rui and Li, Qin and Wang, Ying and Liu, Shijing and Chen, Lu and Zhou, Yan and Zeng, Chen and Zeng, Yan and Xiong, Yun and Zhang, Qian and Li, Na and Du, Peng and Liu, Lin and Chen, Jiyu and He, Yan},
title = {Population pharmacokinetic study of the effect of polymorphisms in the ABCB1 and CES1 genes on the pharmacokinetics of dabigatran},
journal = {Frontiers in Pharmacology},
year = {2024},
volume = {15},
doi = {10.3389/fphar.2024.1454612}
}
EUVIMED